Clustering data with hclust algorithm for PGD2 and other lipid mediator changes in mouse adipose associated with administration of an oral inhibitor of H-PGDS (HQL-79) (Study ST000593)
Reversed phase POSITIVE ION MODE (Analysis AN000909)| Metabolite | Structure | F1 | F2 |
|---|---|---|---|
| 2-LG | ME170924 | 0.78 | 1.22 |
| 2-OG | ME170922 | 0.77 | 1.23 |
| 1-AG | ME170925 | 0.74 | 1.26 |
| 2-AG | ME170926 | 0.71 | 1.29 |
| Dihomo GLA EA | ME170932 | 0.88 | 1.12 |
| 1-OG | ME170921 | 0.90 | 1.10 |
| DEA | ME170934 | 0.89 | 1.11 |
| 1-LG | ME170923 | 0.84 | 1.16 |
| AEA | ME170933 | 0.86 | 1.14 |
| PGF2a EA | ME170936 | 0.98 | 1.02 |
| LEA | ME170930 | 0.95 | 1.05 |
| PEA | ME170927 | 0.95 | 1.05 |
| NO-Gly | ME170937 | 0.93 | 1.07 |
| SEA | ME170928 | 0.93 | 1.07 |
| DHEA | ME170935 | 0.91 | 1.09 |
| aLEA | ME170931 | 0.92 | 1.08 |
| OEA | ME170929 | 0.92 | 1.08 |
Factors:
| F1 | Treatment:HQL-79 |
| F2 | Treatment:Vehicle |
